Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Trilostane, a 3beta-hydroxysteroid dehydrogenase inhibitor, has been used successfully over the last few years for the treatment of canine pituitary-dependent hyperadrenocorticism. In a prospective study of 19 dogs with pituitary-dependent hyperadrenocorticism, the adrenal glands were measured before and at least 6 months after initiation of trilostane therapy. Right adrenal gland length and caudal pole thickness and left adrenal gland caudal pole thickness increased significantly (p < or = 0.05); there was no significant change in left adrenal gland length. Enlargement of adrenal glands during trilostane therapy may occur as a result of suppression of the negative feedback mechanism affecting cortisol production.
Mantis
Panagiotis
P
Department of Veterinary Clinical Sciences, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire AL9 7TA, UK.
Lamb
Christopher R
CR
Witt
Angela L
AL
Neiger
Reto
R
D015096:3-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D000311:Adrenal Glands / Q000000981:diagnostic imaging* / Q000187:drug effects; D000308:Adrenocortical Hyperfunction / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D013196:Dihydrotestosterone / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D004283:Dog Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D008297:Male; D011446:Prospective Studies; D016896:Treatment Outcome; D014463:Ultrasonography
D004791:Enzyme Inhibitors; D013196:Dihydrotestosterone; D015096:3-Hydroxysteroid Dehydrogenases; C009954:trilostane